|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
CLICK ON THE BLUE LINKS TO READ THE FULL STORIES | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Wednesday, October 4
Lucentis Stalls Blood Vessel Growth in Macular Degeneration - CME Teaching Brief� - MedPage TodayLucentis (ranibizumab) is an effective treatment for neovascular age-related macular degeneration, according to two large randomized controlled trials.
Action Points One of the reports found that over two years, on average, patients receiving injections of Lucentis gained more than one line of visual acuity on a standard eye chart, whereas those receiving sham injections lost more than two lines. The second study found that at one year the average patient receiving Lucentis gained about two lines of visual acuity. By contrast, the average patient receiving photodynamic therapy as a sham treatment lost about two lines on the eye chart. In both studies, which appeared, in the Oct. 5 issue of the New England Journal of Medicine. the most feared complication, bacterial infection inside the eye, occurred in one of every 2,000 injections..... |